Dabigatran approved for VTE prevention and treatment

The novel oral anticoagulant dabigatran has been approved for treating and reducing the risk of recurrence of deep venous thrombosis and pulmonary embolism, based on the results of four phase III...

Field of Interest: Cardiology
Type: News Item

VIDEO: PCSK9 inhibitors placed in perspective

WASHINGTON – "We’re at the dawn of an era of biological therapeutics in cardiology," Dr. Peter Libby, chief of cardiovascular medicine at the Brigham and Women’s Hospital in Boston, told us...

Field of Interest: Cardiology
Type: News Item

VIDEO: Rethink the VTE prophylaxis mantra

LAS VEGAS – Venous thromboembolism prophylaxis – a sine qua non of the Joint Commission and others – doesn’t seem to prevent deep vein thrombosis or pulmonary embolism in hospitalized medical...

Field of Interest: Cardiology
Type: News Item

VIDEO: Exploring SYMPLICITY’s failure, Part 2

WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to...

Field of Interest: Cardiology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.